Is NAD+ FDA approved? What the IV studies, supplement rulings and compounding lists show

By · Published · Updated · 8 min read · 14 sources, 14 checked at the source

AI-generated image: an empty recliner beside an unused IV pole in a wellness lounge, with a small vial labeled NAD+ on a side table.

NAD+ has gone from a biochemistry-textbook term to a wellness-menu item in a few short years. You'll see it offered as an IV drip at clinics, as an add-on at telehealth companies, and in supplement form as NR or NMN. The question underneath all of it is simple: has FDA approved NAD+ for anything? We checked FDA's drug database and found no approved NAD+ product. What exists instead is a patchwork of compounding rules, supplement rulings and a small but growing pile of human studies.

Facts are as of November 4, 2026. Sources, with retrieval dates, are at the bottom.

Updated November 10, 2026. For how NAD+ compares with sermorelin and glutathione, see our side-by-side research and status page.

The gist

  • We found no FDA-approved drug containing NAD+ in FDA's Drugs@FDA database on November 4, 2026. [V]
  • NAD and NADH sit in Category 1An interim FDA group of nominated bulk ingredients that FDA generally does not object to pharmacies using while its review continues. Not an approval. Glossary entry of FDA's 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry compounding list (updated May 14, 2026), meaning FDA is still evaluating them. A specific salt form of NAD sits in Category 3. [V]
  • Oral precursors (NR and NMN) reliably raise NAD+ levels in human trials, but a 2026 systematic reviewA review that collects studies on one question by a stated search method, often pooling their numbers. Glossary entry found effects on health outcomes mixed and often null. [V]
  • That same review found no outcome trials of IV or intramuscular NAD+ for wellness or anti-aging use. [V]
  • FDA ruled in September 2025 that NMN can be sold as a dietary supplement, reversing its 2022 position. [V]

A coenzyme, not a peptide

First, a correction to a common assumption: NAD+ isn't a peptide. Nicotinamide adenine dinucleotide is a coenzyme built from two nucleotides, and cells rely on it for a long list of metabolic reactions, plus enzymes involved in DNA repair. [V] It ends up on a peptide site because it shows up on the same clinic menus and the same FDA compounding list as peptides like glutathione and BPC-157. Our glutathione status page is the closest companion to this one.

The research interest is real, and it's not fringe. Levels of NAD+ fall with age in many tissues, and that's driven a decade of trials asking whether topping it up does anything useful. [V]

The promising part of the evidence

Start with what's held up. When people take the precursors nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) by mouth, NAD+ markers in blood go up. That's been shown in randomized trials since at least 2018, when a placebo-controlled crossover trial in healthy middle-aged and older adults found NR was well tolerated and raised NAD+ metabolism over six-week periods. [V] A 2026 head-to-head trial in 65 people found NR and NMN both raised blood NAD+ over 14 days, while plain nicotinamide didn't. Most of its authors work for Nestlé, the paper discloses. [V]

A few small human trials report effects beyond blood levels:

  • Insulin sensitivity (2021, Science). In postmenopausal women with prediabetes and excess weight, ten weeks of NMN raised muscle insulin sensitivity, which didn't change on placebo. One author disclosed a related patent interest. [V]
  • COPD (2024, Nature Aging). In 40 patients, six weeks of NR lowered IL-8, an inflammation marker in sputum, versus placebo. Some authors worked for an NR supplement maker. [V]

Those are single, short trials, and each measured a lab marker rather than how people felt or functioned. [S]

  • 33human intervention studies in a 2026 systematic review of NAD+ boosters [V]
  • 0outcome trials of IV or intramuscular NAD+ that review could include [V]
  • 17FDA enforcement reports for compounded NAD or NADH products since 2017, by our count [V]

Where the evidence thins out

The broadest look we found is a PRISMA-guided systematic review published in Ageing Research Reviews in 2026. It covered 113 studies, including 33 human intervention studies, from 2010 to October 2025. [V] Its authors concluded that oral NR and NMN consistently hit their biochemical target and were generally well tolerated. Effects on functional, metabolic and vascular outcomes, though, were mixed and often null. [V] A separate 2026 meta-analysis of 15 NMN trials found no increase in adverse events, and apart from a slight drop in diastolic blood pressure, no clear metabolic benefit. [V]

A 2025 trial in 58 adults with long COVID makes the gap concrete. NR raised NAD+ levels, but cognition, fatigue, sleep and mood didn't improve compared with placebo. [V]

Claim

An NAD+ drip "recharges" your cells.

What research shows

  • Wellness marketing language

Oral precursors raise blood NAD+ markers in randomized trials. A 2019 pilot found NAD+ given by IV didn't show up as a rise in blood levels for the first two hours. [V]

What is unknown

Whether IV NAD+ improves any health outcome. A 2026 review found no outcome trials to include. [V]

This card describes the kind of research that exists.

The IV question

IV NAD+ has the thinnest record of all. The 2019 pilot above infused NAD+ over six hours in a small group and reported that it was "rapidly and completely removed" from plasma for at least the first two hours. Two authors were affiliated with an NAD+ research company and a wellness center. [V] A 2026 chart review from a commercial wellness chain compared IV NAD+ with IV NR. People on NAD+ reported moderate to severe stomach symptoms, a faster heart rate and chest pressure during infusions, which stretched sessions to about 97 minutes on average versus 37 for NR. All of its authors worked for that chain. [V]

Where NAD+ sits with FDA

Here's the regulatory picture, piece by piece.

Drug approval. We searched Drugs@FDA through openFDA for NAD+ and its drug name, nadide, and found no approved application. [V]

Compounding. FDA's 503A nominations list puts "Nicotinamide Adenine Dinucleotide (NAD)" and the reduced form NADH in Category 1. [V] Category 1 means FDA is evaluating the substance and, for now, doesn't plan to act against pharmacies that compound with it under its conditions. It isn't an approval. [V] A disodium salt trihydrate form sits in Category 3, which covers substances nominated without enough supporting information. [V] Our categories explainer has the details. NAD+ isn't one of the six peptides in HHS's October 2026 interim policy. [V] Glutathione, another IV-menu regular, sits in the same Category 1, and its status page covers its recent recalls. Our legal-status guide explains how compounding fits next to approval and the supplement rules.

Supplements. On September 29, 2025, FDA answered a citizen petition and concluded NMN "is not excluded" from the dietary supplement definition, because evidence showed it was sold as a supplement in the U.S. as early as 2017, before it was authorized for study as a new drug. [V] That reversed the reading FDA gave in a November 2022 response. The agency also noted it can still use its usual tools, including recalls and seizures, against a supplement that's unsafe or adulterated. [V] Our supplement label guide covers what those labels can leave out, and our longevity claims page covers what sellers can say.

Limits and unknowns

Recalls are part of this story. By our count, FDA's enforcement data lists 17 reports for compounded NAD or NADH products from 10 firms since January 2017. Most were Class II, many for lack of sterility assurance. [V] One, reported October 15, 2025, was Class I, for elevated endotoxin levels. The newest was reported October 14, 2026. [V]

We didn't find a large, long-term trial showing NAD+, by drip or by precursor pill, improves a health outcome in people. [U] Several of the human studies above were funded or run by companies that make NAD-related products, which the papers disclose. [V] And openFDA's recall data depends on how products were described, so our count is a floor, not a census. [S] If FDA moves NAD out of Category 1 in either direction, this page gets updated first.

Peptide Policy Watch

Is NAD+ FDA approved? What the IV studies, supplement rulings and compounding lists show

Published November 4, 2026 · https://peptidepolicywatch.com/2026/11/04/is-nad-plus-fda-approved-iv-studies-compounding-status/

Printable checklist

Questions for your clinician

Print or copy these questions for your next visit with a clinician or pharmacist.

  1. Is this an FDA-approved medicine, a compounded drug, or something with no approval for human use?
  2. What do the studies in people show, how large and how long were they, and where can I read them?
  3. How might my own health history, conditions and current medicines change how this applies to me?
  4. Is there an official label or other primary document I can read, and who would know if something goes wrong?

Print view Select it, then use your browser’s Print command to print only this box.

Common questions

Is NAD+ FDA approved?

No. We found no FDA-approved drug containing NAD+ in Drugs@FDA on November 4, 2026. NAD and NADH sit in Category 1 of FDA's 503A compounding list, which means FDA is still evaluating them. [V] Source: openFDA Drugs@FDA; FDA 503A bulk drug substances page

Are there trials of IV NAD+?

Very few. A 2026 systematic review of 33 human studies of NAD+ boosters found no outcome trials of IV or intramuscular NAD+ that it could include. Most trials test oral precursors such as NR and NMN. [V] Source: Gallagher & Emmanuel, Ageing Research Reviews 2026 (PubMed 41655607)

Is NMN allowed as a dietary supplement?

Yes, for now. In a September 29, 2025 petition response, FDA concluded NMN can be sold as a supplement because it was marketed that way in the U.S. before anyone was authorized to study it as a drug. [V] Source: FDA response to citizen petition FDA-2023-P-0872

Sources (retrieved November 4, 2026 unless noted)

  1. openFDA Drugs@FDA search for nicotinamide adenine dinucleotide and nadide (no matching application) [V] — https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:"NICOTINAMIDE+ADENINE+DINUCLEOTIDE"
  2. FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Categories 1-3), updated May 14, 2026 (retrieved November 3, 2026) [V] — https://www.fda.gov/media/94155/download
  3. Gallagher C, Emmanuel OO, "NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinicalResearch done before any testing in people, such as lab-dish and animal studies. Glossary entry and clinical evidence," Ageing Research Reviews, April 2026, PubMed 41655607 [V] — https://pubmed.ncbi.nlm.nih.gov/41655607/
  4. Martens CR et al., randomized crossover trial of nicotinamide riboside in healthy middle-aged and older adults, Nature Communications, March 29, 2018, PubMed 29599478 [V] — https://pubmed.ncbi.nlm.nih.gov/29599478/
  5. Christen S et al., Nature Metabolism, January 2026 (NR, NMN and nicotinamide compared), PubMed 41540253 [V] — https://pubmed.ncbi.nlm.nih.gov/41540253/
  6. Yoshino M et al., "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women," Science, June 11, 2021, PubMed 33888596 [V] — https://pubmed.ncbi.nlm.nih.gov/33888596/
  7. Norheim KL et al., Nature Aging, December 2024 (NR in COPD), PubMed 39548320 [V] — https://pubmed.ncbi.nlm.nih.gov/39548320/
  8. Yang W et al., "Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults," Nutrients, July 10, 2026, PubMed 42514320 [V] — https://pubmed.ncbi.nlm.nih.gov/42514320/
  9. Wu CY et al., "Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial," EClinicalMedicine, November 12, 2025, PubMed 41357333 [V] — https://pubmed.ncbi.nlm.nih.gov/41357333/
  10. Grant R et al., "A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD," Frontiers in Aging Neuroscience, September 12, 2019, PubMed 31572171 [V] — https://pubmed.ncbi.nlm.nih.gov/31572171/
  11. Reyna K et al., "Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR)," Frontiers in Aging, February 2, 2026, PubMed 41704678 [V] — https://pubmed.ncbi.nlm.nih.gov/41704678/
  12. FDA, response to citizen petition FDA-2023-P-0872 on NMN, September 29, 2025 (read via AHPA's posted copy) [V] — https://downloads.regulations.gov/FDA-2023-P-0872-2754/attachment_1.pdf
  13. openFDA drug enforcement reports for NAD and NADH products, 2017 to October 14, 2026 [V] — https://api.fda.gov/drug/enforcement.json?search=product_description:"nicotinamide+adenine+dinucleotide"&limit=50
  14. FDA, "Recalls Background and Definitions" [V] — https://www.fda.gov/safety/industry-guidance-recalls/recalls-background-and-definitions
Cite or link to this page

Peptide Policy Watch staff. “Is NAD+ FDA approved? What the IV studies, supplement rulings and compounding lists show.” Peptide Policy Watch. Published November 4, 2026. Updated November 10, 2026. https://peptidepolicywatch.com/2026/11/04/is-nad-plus-fda-approved-iv-studies-compounding-status/

Link: https://peptidepolicywatch.com/2026/11/04/is-nad-plus-fda-approved-iv-studies-compounding-status/

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits